netupitant   Click here for help

GtoPdb Ligand ID: 5742

Synonyms: Ro 67-31898/000 | Ro-673189000
Approved drug PDB Ligand
netupitant is an approved drug (FDA (2014), EMA (2015))
Compound class: Synthetic organic
Comment: Netupitant is a selective tachykinin receptor 1 (NK1) receptor antagonist.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: netupitant

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 8
Topological polar surface area 39.68
Molecular weight 578.25
XLogP 7.55
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CN1CCN(CC1)c1ncc(c(c1)c1ccccc1C)N(C(=O)C(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)(C)C)C
Isomeric SMILES CN1CCN(CC1)c1ncc(c(c1)c1ccccc1C)N(C(=O)C(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)(C)C)C
InChI InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3
No information available.
Summary of Clinical Use Click here for help
Netupitant is approved as a component of the fixed-dose drug Akynzeo®, the other component being palonosetron. This orally administered drug mixture is a prophylactic used to provide supportive care for patients receiving emetogenic chemotherapy, and is superior in action to palonosetron alone [1].
In April 2018 the FDA approved a modified formulation of Akynzeo® that is designed for i.v. infusion, and contains fosnetupitant (phosphorylated netupitant; PubChem CID 71544786) in place of netupitant.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Netupitant is an antagonist of the neurokinin type 1 receptor (NK1) and palonosetron is a serotonin 5-HT3 receptor antagonist. These compounds act together to inhibit pathways involved in emesis [1].
External links Click here for help